1. Upregulation of GPX4 drives ferroptosis resistance in scleroderma skin fibroblasts.
- Author
-
Zhang F, Xiao Y, Huang Z, Wang Y, Wan W, Zou H, Wang B, Qiu X, and Yang X
- Subjects
- Female, Humans, Antigens, CD metabolism, Antigens, CD genetics, Carbolines, Cells, Cultured, Iron metabolism, Phenanthridines pharmacology, Piperazines, Receptors, Transferrin metabolism, Receptors, Transferrin genetics, Up-Regulation, Ferroptosis drug effects, Fibroblasts metabolism, Fibroblasts pathology, Fibroblasts drug effects, Phospholipid Hydroperoxide Glutathione Peroxidase metabolism, Phospholipid Hydroperoxide Glutathione Peroxidase genetics, Scleroderma, Systemic pathology, Scleroderma, Systemic metabolism, Scleroderma, Systemic genetics, Skin pathology, Skin metabolism
- Abstract
The pathogenesis of systemic sclerosis (SSC) fibrosis involves the rapid proliferation of skin fibroblasts, and current anti-fibrotic treatments are limited. This study investigated the relationship between ferroptosis and SSC skin fibroblasts. We observed that erastin-induced ferroptosis was suppressed in SSC fibroblasts. RSL3, a direct inhibitor of Glutathione Peroxidase 4 (GPX4), significantly reduced the viability of the fibroblasts, and upregulation of GPX4 in the SSC fibroblasts contributed to ferroptosis resistance. Furthermore, we demonstrated that transferrin receptor 1 (TfR1) was a crucial transporter for iron deposition in the fibroblasts. Collectively, our results highlight that GPX4 inhibition could enhance the sensitivity to ferroptosis by SSC fibroblasts, which showed distinct characteristics of iron metabolism that were not observed in normal fibroblasts in this study. Taken together, these results suggest that targeting ferroptosis could be a therapeutic strategy for the treatment of SSC., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF